{"id":3986,"date":"2017-08-13T07:38:59","date_gmt":"2017-08-13T07:38:59","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/andromedic-esho-2014\/"},"modified":"2026-02-17T09:58:37","modified_gmt":"2026-02-17T09:58:37","slug":"andromedic-esho-2014","status":"publish","type":"page","link":"https:\/\/andromedichyperthermia.com\/fr\/andromedic-esho-2014\/","title":{"rendered":"Andromedic ESHO 2014"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/fr\/andromedic-esho-2014\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/fr\/andromedic-esho-2014\/\",\n      \"name\": \"Essais cliniques avec Andromedic HyDeep 600 WM - Congr\u00e8s ESHO\",\n      \"description\": \"Donn\u00e9es des \u00e9tudes cliniques sur le HyDeep 600 WM pour le cancer du col de l'ut\u00e9rus et \u00e9tudes de faisabilit\u00e9 multicentriques pr\u00e9sent\u00e9es au congr\u00e8s ESHO.\",\n      \"inLanguage\": \"fr-FR\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"mainEntity\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n      \"about\": [\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"\u00c9tude LACC sur le carcinome du col de l'ut\u00e9rus\",\n          \"description\": \"\u00c9tude sur 8 patientes montrant un contr\u00f4le local de 100 % en utilisant le syst\u00e8me HyDeep 600 WM et la curieth\u00e9rapie HDR.\",\n          \"studySubject\": { \"@type\": \"MedicalCondition\", \"name\": \"Cancer du col de l'ut\u00e9rus\" }\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"\u00c9tude cas-t\u00e9moin en Espagne\",\n          \"description\": \"\u00c9tude de faisabilit\u00e9 \u00e0 grande \u00e9chelle portant sur 293 patients r\u00e9partis sur 9 sites tumoraux.\",\n          \"sampleSize\": 293,\n          \"studyStatus\": \"Published\"\n        }\n      ],\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-salvatore-conte\/\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" }\n      ]\n    },\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"HyDeep 600WM\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"Syst\u00e8me avanc\u00e9 d'hyperthermie oncologique \/ dispositif professionnel d'hyperthermie locale profonde par RF modul\u00e9e (13,56 MHz).\",\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/fr\/contact\/\",\n        \"priceSpecification\": {\n          \"@type\": \"PriceSpecification\",\n          \"description\": \"Prix sur demande\"\n        }\n      },\n      \"review\": {\n        \"@type\": \"Review\",\n        \"author\": { \"@type\": \"Person\", \"name\": \"Dr. med. Veronica Iatan\" },\n        \"reviewRating\": { \"@type\": \"Rating\", \"ratingValue\": \"5\", \"bestRating\": \"5\" },\n        \"reviewBody\": \"Technologie de pointe pour l'hyperthermie profonde avec des protocoles valid\u00e9s cliniquement.\"\n      }\n    },\n    {\n      \"@type\": \"MedicalOrganization\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\",\n      \"name\": \"Andromedic Srl\"\n    }\n  ]\n}\n<\/script><\/p>\n<div style=\"line-height: 1.6; color: #333; max-width: 1100px; margin: auto; font-family: 'Segoe UI', Helvetica, sans-serif; background-color: #fff; padding: 20px;\">\n<header style=\"border-bottom: 4px solid #1a2a6c; padding-bottom: 25px; margin-bottom: 40px; text-align: center;\">\n<h1 style=\"color: #1a2a6c; font-size: 28px; font-weight: 800; text-transform: uppercase; margin-bottom: 10px;\">European Society for Hyperthermic Oncology : ESHO 2014<\/h1>\n<h2 style=\"color: #b21f1f; font-size: 20px; font-weight: 600;\">Intervention d&rsquo;Andromedic \u2013 Dr Salvatore Conte<\/h2>\n<p style=\"font-size: 16px; max-width: 850px; margin: 15px auto; color: #555;\">Lors de l&rsquo;<a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\">ESHO 2014<\/a>, le <a href=\"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-salvatore-conte\/\"><strong>Dr Salvatore Conte<\/strong><\/a> a annonc\u00e9 une \u00e9tape majeure pour l&rsquo;\u00e9quipe d&rsquo;hyperthermie d&rsquo;Andromedic : la fabrication et la livraison r\u00e9ussies de 25 <a href=\"https:\/\/andromedichyperthermia.com\/fr\/dispositif-dhyperthermie-locale\/\">dispositifs d&rsquo;hyperthermie locale profonde <strong>HyDeep 600WM<\/strong><\/a> en seulement 18 mois, avec 40 unit\u00e9s suppl\u00e9mentaires destin\u00e9es \u00e0 l&rsquo;Inde.<\/p>\n<\/header>\n<div style=\"margin-bottom: 50px; border-radius: 15px; overflow: hidden; box-shadow: 0 10px 25px rgba(0,0,0,0.2);\">\n<p><iframe loading=\"lazy\" title=\"intervento Andromedic   Esho 20014\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/fgMdXxoJ1cI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<\/div>\n<h2 style=\"text-align: center; color: #1a2a6c; margin-bottom: 30px; text-transform: uppercase;\">\u00c9tudes cliniques pr\u00e9sent\u00e9es : HyDeep 600 WM &#8211; Hyperthermie oncologique avanc\u00e9e<\/h2>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #1a2a6c; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">1. Chimioradioth\u00e9rapie + Hyperthermie + Brachyth\u00e9rapie HDR pour le LACC<\/h3>\n<\/div>\n<div style=\"padding: 30px; background: #f9f9f9;\">\n<p><strong>OBJECTIFS :<\/strong> \u00c9tudier les r\u00e9sultats de la combinaison du cisplatine hebdomadaire et de l&rsquo;hyperthermie locale profonde avec l&rsquo;IMRT, suivie d&rsquo;une brachyth\u00e9rapie (BRT) pour le carcinome du col de l&rsquo;ut\u00e9rus localement avanc\u00e9 (LACC).<\/p>\n<div style=\"background: #fff; padding: 20px; border-radius: 10px; margin: 20px 0; border-left: 5px solid #b21f1f;\">\n<p><strong>MAT\u00c9RIELS ET M\u00c9THODES :<\/strong><\/p>\n<ul style=\"margin-top: 10px; font-size: 15px;\">\n<li><strong>Groupe de patients :<\/strong> 8 patientes (3 stade IIB, 1 IIIB, 2 NEI, 3 LRCC).<\/li>\n<li><strong>Protocole :<\/strong> 50,4 Gy aux ganglions pelviens avec SIB au GTV (61,8 Gy au total) en 28 fractions. Dose de BRT : 21 Gy en 3 fractions.<\/li>\n<li><strong>Th\u00e9rapie concomitante :<\/strong> Cisplatine hebdomadaire 40mg\/m\u00b2 + HT une fois par semaine.<\/li>\n<\/ul>\n<\/div>\n<div style=\"background: #e8f5e9; padding: 20px; border-radius: 10px; border: 1px solid #2e7d32;\">\n<p><strong style=\"color: #1b5e20; font-size: 17px; display: block; margin-bottom: 10px;\">R\u00c9SULTATS ET CONCLUSIONS :<\/strong><\/p>\n<p style=\"font-size: 16px; font-weight: bold; margin: 0;\">100% DE CONTR\u00d4LE LOCAL ATTEINT. Aucune toxicit\u00e9 aigu\u00eb ou tardive de grade 3 \u00e0 4 li\u00e9e au traitement n&rsquo;a \u00e9t\u00e9 observ\u00e9e.<\/p>\n<p style=\"margin-top: 10px; font-style: italic;\">\u00ab\u00a0L&rsquo;ajout de l&rsquo;hyperthermie locale profonde \u00e0 la chimioradioth\u00e9rapie repr\u00e9sente une nouvelle strat\u00e9gie prometteuse avec une excellente tol\u00e9rance.\u00a0\u00bb<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #b21f1f; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">2. \u00c9tude de quasi-faisabilit\u00e9 (Cas-T\u00e9moin) \u2013 Hyperthermie locale profonde &#8211; Andalousie, Espagne<\/h3>\n<\/div>\n<div style=\"padding: 30px;\">\n<p><strong>Introduction :<\/strong> Le premier essai clinique en Espagne combinant l&rsquo;hyperthermie locale profonde avec les traitements anticanc\u00e9reux standards au sein du syst\u00e8me de sant\u00e9 publique.<\/p>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 25px 0;\">\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Conception de l&rsquo;\u00e9tude :<\/strong> \u00c9tude prospective cas-t\u00e9moin. 293 patients au total (97 en phase active vs 196 t\u00e9moins). 9 localisations tumorales.<\/div>\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Param\u00e8tres du traitement :<\/strong> 10 s\u00e9ances (2-3\/semaine), dur\u00e9e d&rsquo;une heure, 150W\u2013400W utilisant le <strong>dispositif d&rsquo;hyperthermie modul\u00e9e HyDeep 600WM<\/strong>.<\/div>\n<\/div>\n<h4 style=\"color: #1a2a6c; border-bottom: 2px solid #b21f1f; display: inline-block; padding-bottom: 5px;\">Donn\u00e9es pr\u00e9liminaires (sous-groupe de 22 patients) :<\/h4>\n<ul style=\"margin-top: 15px; font-size: 14px; column-count: 2;\">\n<li><strong>Glioblastome (2c)<\/strong><\/li>\n<li><strong>T\u00eate et cou (7c)<\/strong><\/li>\n<li><strong>Rectum pr\u00e9op\u00e9ratoire (3c)<\/strong><\/li>\n<li><strong>Cancer du sein (3c)<\/strong><\/li>\n<li><strong>Poumon (NSCLC &#8211; 11c)<\/strong><\/li>\n<li><strong>Prostate (4c)<\/strong><\/li>\n<li><strong>Col de l&rsquo;ut\u00e9rus et m\u00e9tastases<\/strong><\/li>\n<\/ul>\n<div style=\"display: flex; flex-wrap: wrap; gap: 15px; margin: 25px 0;\">\n<div style=\"flex: 1; min-width: 200px; background: #fffde7; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #fbc02d;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">81.2%<\/span><br \/>\n<strong>HAUTE TOL\u00c9RANCE<\/strong><br \/>\n<small>Patients satisfaits ou tr\u00e8s satisfaits<\/small><\/div>\n<div style=\"flex: 1; min-width: 200px; background: #f1f8e9; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #7cb342;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">66.6%<\/span><br \/>\n<strong>Z\u00c9RO TOXICIT\u00c9<\/strong><br \/>\n<small>Aucun effet ind\u00e9sirable signal\u00e9<\/small><\/div>\n<\/div>\n<p style=\"background: #f4f7f9; padding: 15px; border-radius: 8px; border-left: 4px solid #1a2a6c;\"><strong>CONCLUSION :<\/strong> L&rsquo;hyperthermie locale profonde est r\u00e9alisable dans les soins hospitaliers publics de routine sans ressources extraordinaires. Une s\u00e9lection appropri\u00e9e des patients garantit une toxicit\u00e9 minimale (Grade 1).<\/p>\n<div style=\"text-align: center; margin-top: 30px;\"><a style=\"display: inline-block; background: #b21f1f; color: #fff; padding: 14px 30px; text-decoration: none; border-radius: 5px; font-weight: 800; text-transform: uppercase; box-shadow: 0 4px 10px rgba(178,31,31,0.3);\" href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Protocolo-del-ensayo-MAG-HIP-2013-01-11-EN.pdf\">T\u00e9l\u00e9charger le protocole complet de l&rsquo;\u00e9tude (PDF)<\/a><\/div>\n<\/div>\n<\/section>\n<div style=\"margin-top: 40px;\">\n<h3 style=\"text-align: center; color: #1a2a6c; text-transform: uppercase; letter-spacing: 1px;\">Posters scientifiques et documentation ESHO<\/h3>\n<div id='gallery-1' class='gallery galleryid-3986 gallery-columns-1 gallery-size-full'><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/fr\/preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"590\" height=\"837\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1329\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg 590w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-211x300.jpg 211w\" sizes=\"auto, (max-width: 590px) 100vw, 590px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1329'>\n\t\t\t\tPreliminary results of chemoradiation plus Andromedic hyperthermia and high dose rate brachytherapy for locally advanced cervical carcinoma\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/fr\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-b-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"569\" height=\"831\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1308\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg 569w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B-205x300.jpg 205w\" sizes=\"auto, (max-width: 569px) 100vw, 569px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1308'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia treatment with standard cancer treatments and describing patterns of response ESHO\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/fr\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"568\" height=\"826\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1287\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1287'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia HyDeep 600WM treatment with standard cancer treatments and describing patterns of response\n\t\t\t\t<\/figcaption><\/figure>\n\t\t<\/div>\n\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>European Society for Hyperthermic Oncology : ESHO 2014 Intervention d&rsquo;Andromedic \u2013 Dr Salvatore Conte Lors de l&rsquo;ESHO 2014, le Dr Salvatore Conte a annonc\u00e9 une \u00e9tape majeure pour l&rsquo;\u00e9quipe d&rsquo;hyperthermie d&rsquo;Andromedic : la fabrication et la livraison r\u00e9ussies de 25 dispositifs d&rsquo;hyperthermie locale profonde HyDeep 600WM en seulement 18 mois, avec 40 unit\u00e9s suppl\u00e9mentaires destin\u00e9es&hellip;<\/p>\n","protected":false},"author":1,"featured_media":17341,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-gutentor-full-width.php","meta":{"footnotes":""},"class_list":["post-3986","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/pages\/3986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/comments?post=3986"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/pages\/3986\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/media\/17341"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/media?parent=3986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}